Voyager Acquisition (VACH) and VERAXA Biotech have agreed to merge, forming a publicly traded, clinical-stage biopharma company focused on next-gen cancer treatments, the companies said Wednesday.
The companies said that post-merger, VERAXA will trade on the Nasdaq under the ticker 'VERX.'
The deal values VERAXA at $1.3 billion, with shareholders receiving 130 million shares in the new entity, the companies said, adding no cash proceeds will go to existing VERAXA shareholders, who will roll over their equity.
Assuming a $10 per share valuation and no Voyager shareholder redemptions, the combined company's implied equity value is $1.64 billion, they added.
VERAXA may gain access to up to $253 million in cash held by Voyager, pending transaction costs and shareholder approvals, the companies said.
They added that VERAXA is also raising additional funds to support operations for the next two years.
The merger is expected to close in Q4.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。